Fresno, N.; Macías-Gonzalez, M.; Torres-Zaguirre, A.; Romero-Cuevas, M.; Sanz-Camacho, P.; Elguero, J.; Pavon,́ F.J.; Rodríguez de Fonseca, F.; Goya, P.; Pérez-Fernández, R.
[2015]. Novel oxazolidinone-based peroxisome proliferator activated receptor agonists: molecular modeling, synthesis, and biological evaluation. J. Med. Chem, 2015, 58, 6639-6652.
Morales-García, J. A.; Palomo, V.; Redondo, M.; Alonso-Gil, S.; Gil, C.; Martinez, A.; Perez-Castillo, A.
[2014]. Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3, two relevant therapeutic targets for neurological disorders. ACS Chem. Neurosci. 2014, 5, 194-204
Garcia, A. M.; Redondo, M.; Martinez, A.; Gil, C.
[2014]. Phosphodiesterase 10 inhibitors: A new strategy for Parkinson’s disease pharmacological therapy. Curr. Med. Chem. 2014, 10, 1171-1187
Salado, I. G.; Redondo, M.; Bello, M. L.; Perez, C.; Liachko, N. F.; Kraemer, B. C.; Miguel, L.; Lecourtois, M.; Gil, C.; Martinez, A.; Perez, D. I.
[2014]. Protein kinase CK-1 inhibitors as new potential drugs for Amyotrophic Lateral Sclerosis. J. Med. Chem. 2014, 57, 2755-2772
Gonzalez-Naranjo, P.; Perez-Macias, N.; Campillo, N. E.; Perez, C.; Aran, V. J.; Giron, R.; Sanchez-Robles, E.; Martin, M. I.; Gomez-Canas, M.; Garcia-Arencibia, M.; Fernandez- Ruiz, J.; Paez, J. A.,
[2014]. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. Eur J Med Chem, 2014, 73, 56-72
Pérez, C.; Ruiz del Castillo, M. L.; Gil, C.; Blanch, G. P.; Flores, G.
[2014]. Anthocyanins constituents, antioxidant and anti-Inflammatory activity of strawberries. Comparison with other berry fruits. En Strawberries: Cultivation, antioxidant properties and health benefits. Ed. N. Malone. Nova Science Publishers, Inc. 2014, 39-54.
González-Muñoz, M.; Rodríguez-Mahillo, A. I.; Gil, C.; Morán, Y.; Moneo, I.; Martínez, A.; Mora, J. S.
[2014]. Glycogen synthase kinase-3β expression and phosphorylation in peripheral blood mononuclear cells of patients with Amyotrophic Lateral Sclerosis. Br. J. Med. Med. Res. 2014, 4, 263-271
García, A. M.; Brea, J.; Morales-García, J. A.; Perez, D. I.; González, A.; Alonso-Gil, S.; Gracia-Rubio, I.; Ros-Simó, C.; Conde, S.; Cadavid, M. I.; Loza, M. I.; Perez-Castillo, A.; Valverde, O.; Martinez, A.; Gil, C.
[2014]. Modulation of cAMP specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. J. Med. Chem. 2014, 57, 8590-8607
Martinez, A.; Gil, C.
[2014]. cAMP specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Exp. Opin. Ther. Patents 2014, 24, 1311-1321.
Salado IG, Redondo M, Bello ML, Perez C, Liachko NF, Kraemer BC, Miguel L, Lecourtois M, Gil C, Martinez A, Perez DI
[2014]. Protein kinase CK-1 inhibitors as new potential drugs for Amyotrophic Lateral Sclerosis. J. Med. Chem. 73:56-72
P. Gonzalez-Naranjo, N. Perez-Macias, N. E. Campillo, C. Perez, V. J. Aran, R. Giron, E. Sanchez-Robles, M. I. Martin, M. Gomez-Canas, M. Garcia-Arencibia, J. Fernandez-Ruiz and J. A. Paez
[2014]. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer´s disease. Eur J Med Chem 73: 56-72
Lipina, T. V.; Palomo, V.; Gil, C.; Martinez, A.; Roder, J. C.
[2013]. Dual inhibitor of PDE7 and GSK-3 - VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology 2013, 64, 205-214
Morales-Garcia, J.; Susin, C.; Alonso-Gil, S.; Perez, D. I.; Palomo, V.; Perez, C.; Conde, S.; Santos, A.; Gil, C.; Martinez, A.; Perez-Castillo, A.
[2013]. Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem. Neurosci. 2013, 4, 350-360
Perez-Gonzalez, R.; Pascual, C.; Antequera, D.; Bolos, M.; Redondo, M.; Perez, D. I.; Pérez-Grijalba, V.; Krzyzanowska, A.; Sarasa, M.; Gil, C.; Ferrer, I.; Martinez, A.; Carro, E
[2013]. Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiol. Aging 2013, 34, 2133-2145
Emerging drugs and targets for Parkinson’s disease. Ed. A. Martinez, C. Gil.
[2013]. Royal Society of Chemistry. 2013, ISBN 978-1-84973-617-6
Medina-Rodríguez, E. M.; Arenzana, F. J.; Pastor, J.; Redondo, M.; Palomo, V.; García de Sola, R.; Gil, C.; Martínez, A.; Bribián, A.; de Castro, F.
[2013]. Inhibition of endogenous Phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cell. Mol. Life Sci. 2013, 70, 3449-3462
González-García, C.; Bravo, B.; Ballester, A.; Gómez-Pérez, R.; Eguiluz, C.; Redondo, M.; Martínez, A.; Gil, C.; Ballester, S.
[2013]. Comparative assessment of phosphodiesterase 4 and 7 inhibitors as therapeutic agents in Experimental Autoimmune Encephalomyelitis. Br. J. Pharmacol., 2013, 170, 602-613
Martinez, A.; Perez, D. I.; Gil, C.
[2013]. Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer’s disease. Curr. Top. Med. Chem. 2013, 13, 1808-1819
Redondo, M.; Soteras, I.; Brea, J.; Gonzalez-García, A.; Cadavid, M. I.; Loza, M. I.; Martinez, A.; Gil, C.; Campillo, N.
[2013]. Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities. Eur. J. Med. Chem. 2013, 70, 781-788
Pedro González-Naranjo, Concepción Pérez, Nuria E. Campillo and Juan A. Páez.
[2013]. Cannabinoids As Multitarget Drugs For Alzheimer Disease. Curr. Alzheimer Res. 2013, 0(3):229-39
